Inhibitors of mTOR pathway for cancer therapy, moving on from rapalogs to TORKinibs

E-ISSN： 1097-0142|121|19|3390-3392

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.19, 2015-10, pp. : 3390-3392

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The mTOR Pathway in Breast Cancer

By Hynes Nancy Boulay Anne

Journal of Mammary Gland Biology and Neoplasia, Vol. 11, Iss. 1, 2006-01 ,pp. : 53-61

Springer Publishing Company

Access to resources Recommend Favorite

Rechallenge with mTOR Inhibitors in Metastatic Renal Cell Carcinoma Patients Who Progressed on Previous mTOR Inhibitor Therapy

Oncology, Vol. 85, Iss. 1, 2013-06 ,pp. : 8-13

Karger

Access to resources Recommend Favorite

Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2−/− mice

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 4, 2015-04 ,pp. : 1451-1463

John Wiley & Sons Inc

Access to resources Recommend Favorite

mTOR inhibitors in renal cell carcinoma

By Battelli Chiara Cho Daniel C

Therapy, Vol. 8, Iss. 4, 2011-07 ,pp. : 359-367

Future Medicine

Access to resources Recommend Favorite

Immunosuppressive minimization with mTOR inhibitors and belatacept

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 8, 2015-08 ,pp. : 921-927

John Wiley & Sons Inc

Access to resources Recommend Favorite